Lilly brain-plaque diagnostic approved in Europe
Jan 15 (Reuters) - European health regulators on Tuesday approved Eli Lilly and Co's imaging agent used to detect brain plaques that are considered a possible cause of Alzheimer's disease.
It was approved in Europe for use in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of memory and reasoning problems.
The radioactive diagnostic called Amyvid, which is used in conjunction with Positron Emission Tomography (PET) imaging tests, was approved for use in the United States last April.
Amyvid can help detect beta-amyloid plaque build-up in the brain. The plaques, which have been associated with Alzheimer's disease, were previously only detectable through autopsy.
- Children's corpses reveal desperate attempts to escape Korean ferry |
- Russia says it will respond if Ukraine interests attacked |
- Vote delayed on loan guarantee for World Trade Center developer
- Obama seeks to ease Asian allies' doubts during visit to Japan |
- NYPD Twitter campaign backfires, thousands of negative tweets